HC Wainwright Reaffirms “Buy” Rating for Indaptus Therapeutics (NASDAQ:INDP)

Indaptus Therapeutics (NASDAQ:INDP)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 385.83% from the stock’s previous close.

Indaptus Therapeutics Trading Up 1.2 %

Shares of INDP opened at $2.47 on Monday. The company has a market capitalization of $21.09 million, a PE ratio of -1.39 and a beta of 1.30. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08. The stock’s 50-day moving average price is $2.38 and its two-hundred day moving average price is $2.09.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. Equities research analysts predict that Indaptus Therapeutics will post -1.83 EPS for the current fiscal year.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.17% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.